| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
26006 |
| Drug |
Delgocitinib |
| Brand |
Anzupgo® |
| Indication |
Delgocitinib (Anzupgo®) is indicated for the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate. |
| Rapid review commissioned |
16/02/2026 |
| Rapid review completed |
12/03/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of delgocitinib compared with the current standard of care. |
| Full HTA commissioned by the HSE |
13/03/2026 |
| Pre-submission consultation with Applicant |
29/04/2026 |
